On June 12, the FDA approved pembrolizumab for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy with or without cisplatin after surgery, and then as a single agent. 

For more information, read the FDA announcement and the Merck press release.

Posted on 6/17/2025